EricLawrenceSimpsonMD
Dermatology • Portland, ORAssociate Professor, Dermatology, Oregon Health and Science University School of Medicine
Dr. Simpson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-418-3376Fax+1 503-494-6968
Education & Training
Oregon Health & Science University (OHSU Health)Residency, Dermatology, 1999 - 2002
Baylor University Medical CenterInternship, Internal Medicine, 1998 - 1999
University of Texas Southwestern Medical SchoolClass of 1998
Certifications & Licensure
OR State Medical License 2002 - 2025
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Efalizumab for Moderate to Severe Atopic Dermatitis Start of enrollment: 2005 Jun 01
- Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis Start of enrollment: 2007 Apr 01
- Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis Start of enrollment: 2008 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two...Sonja Ständer, Gil Yosipovitch, Eric L Simpson, Brian S Kim, Kenji Kabashima
Advances in Therapy. 2025-04-01 - Functional Skin Barrier Changes after Immersion Versus Showering and Impact of Petrolatum Application.Sabra Leitenberger, Brenda M Simpson, Michael E Jacobson, Emile Latour, Eric L Simpson
Dermatitis. 2025-03-21 - Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age.Michael J Cork, Mette Deleuran, Bob Geng, Jonathan I Silverberg, Eric L Simpson
The Journal of Allergy and Clinical Immunology. in Practice. 2025-03-11
Journal Articles
- Efficacy and Safety of Baricitinib Combined with Topical Corticosteroids for Treatment of Moderate to Severe Atopic DermatitisLawrence F Eichenfield, Eric L Simpson, JAMA Dermatology
- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Hernan Valdez, JAMA Dermatology
- Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesJonathan I Silverberg, Amy S Paller, Mark Boguniewicz, Sarah L Chamlin, Eric L Simpson, Lawrence F Eichenfield, Steven R Feldman, Dermatology and Therapy
Authored Content
- Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJune 2020
Press Mentions
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe EczemaOctober 4th, 2024- Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Atopic Dermatitis, a Chronic Skin ConditionSeptember 30th, 2024
- New Data Show Lilly's EBGLYSS™ (Lebrikizumab-Lbkz) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents with Moderate-to-Severe Atopic DermatitisSeptember 25th, 2024
- Join now to see all
Grant Support
- The Role Of The Skin Barrier In Atopic Dermatitis Development And PreventionNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2012
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
